Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6)
- 1 June 2004
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 14 (6) , 369-379
- https://doi.org/10.1097/00008571-200406000-00006
Abstract
In humans, cytochrome P450 2A6 (CYP2A6) constitutes the principal nicotine C-oxidase. Several different polymorphic CYP2A6 gene variants are known which contribute to the highly variable expression of this enzyme among individuals. In this study we report a novel polymorphism located in the 5' flanking region (-745A > G) of the CYP2A6 gene disrupting a CCAAT box. Electrophoretic mobility shift assays (EMSA) indicated that NF-YA is part of this nuclear protein complex. Chromatin immunoprecipitation revealed that NF-Y recognizes a region of the CYP2A6 5' flanking region located between -932 and -606. EMSA showed that out of the three CCAAT boxes in the CYP2A6 promoter, with CCAAT core sequences located between -839/-835, -748/-744, and -689/-685, only the one at -748/-744 was able to compete with the nuclear protein complex binding to the -748/-744 CCAAT box. Cotransfection experiments indicated that NF-Y acts as a positive regulatory element on CYP2A6 gene regulation. EMSA demonstrated that an NF-Y consensus oligonucleotide but not the -745A > G oligonucleotide competed efficiently with binding of the protein complex to the -748/-744 CCAAT box. Promoter activity of the -745A > G variant was significantly reduced to 78% relative to the wild-type allele in HepG2 cells transfected with luciferase reporter plasmids. Finally, haplotype analysis was carried out comprising the -745A > G variant in combination with all known CYP2A6 3' and 5' flanking single nucleotide polymorphisms: -1013A > G, -48T > G, and the CYP2A6/CYP2A7 3' flank conversion. A new haplotype, CYP2A6*1H was identified, with allele frequencies of 3.1% in Swedish and 5.2% in Turkish populations.Keywords
This publication has 47 references indexed in Scilit:
- A nicotineC-oxidase gene (CYP2A6) polymorphism important for promoter activityHuman Mutation, 2004
- Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9)Pharmacogenetics, 2003
- Characterization of a novelCYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activityHuman Mutation, 2002
- Cooperative Regulation of CYP3A5 Gene Transcription by NF-Y and Sp Family MembersBiochemical and Biophysical Research Communications, 2001
- CYP2A6*6, a Novel Polymorphism in Cytochrome P450 2A6, Has a Single Amino Acid Substitution (R128Q) That Inactivates Enzymatic ActivityPublished by Elsevier ,2001
- A Novel Single Nucleotide Polymorphism Altering Stability and Activity of CYP2A6Biochemical and Biophysical Research Communications, 2001
- Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43Biochemical and Biophysical Research Communications, 2001
- Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolismFEBS Letters, 1999
- High variability of nitrosamine metabolism among individuals: Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N‐nitrosodimethylamine and N‐nitrosodiethylamine in mice and humansMolecular Carcinogenesis, 1993
- A multiplicity of CCAAT box-binding proteinsCell, 1987